See more : Gores Guggenheim, Inc. (GGPIU) Income Statement Analysis – Financial Results
Complete financial analysis of Ayala Pharmaceuticals, Inc. (AYLA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Ayala Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Britvic plc (BTVCF) Income Statement Analysis – Financial Results
- Hurco Companies, Inc. (HURC) Income Statement Analysis – Financial Results
- Bod Science Limited (BOD.AX) Income Statement Analysis – Financial Results
- The Global Ltd. (3271.T) Income Statement Analysis – Financial Results
- Intellivate Capital Ventures Limited (INTELLCAP.BO) Income Statement Analysis – Financial Results
Ayala Pharmaceuticals, Inc. (AYLA)
About Ayala Pharmaceuticals, Inc.
Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, focuses on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers. The company's lead product candidate is AL101, a potent, selective, and injectable small molecule gamma secretase inhibitor (GSI) that is in Phase II clinical trial for the treatment of recurrent/metastatic adenoid cystic carcinoma for patients bearing Notch-activating mutations. It is also involved in developing AL102, a potent, selective, and oral small molecule GSI that is in Phase II/III pivotal study for the treatment of desmoid tumors. Ayala Pharmaceuticals, Inc. has a collaboration agreement with Novartis International Pharmaceutical Limited to develop AL102 for the treatment of multiple myeloma. The company was incorporated in 2017 and is headquartered in Rehovot, Israel.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 692.00K | 0.00 | 3.71M | 2.33M | 0.00 |
| Cost of Revenue | 602.00K | 3.51M | 3.71M | 1.29M | 0.00 |
| Gross Profit | 90.00K | -3.51M | 0.00 | 1.05M | 0.00 |
| Gross Profit Ratio | 13.01% | 0.00% | 0.00% | 44.94% | 0.00% |
| Research & Development | 27.85M | 29.94M | 22.41M | 14.42M | 5.74M |
| General & Administrative | 9.74M | 9.28M | 7.37M | 4.34M | 3.29M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.74M | 9.28M | 7.37M | 4.34M | 3.29M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 37.59M | 39.22M | 29.78M | 18.76M | 9.04M |
| Cost & Expenses | 38.20M | 42.72M | 33.49M | 20.05M | 9.04M |
| Interest Income | 0.00 | 0.00 | 56.00K | 225.00K | 448.00K |
| Interest Expense | -74.00K | -1.55M | 56.00K | 225.00K | 0.00 |
| Depreciation & Amortization | 162.00K | 168.00K | 182.00K | 150.00K | 49.00K |
| EBITDA | -37.50M | -40.86M | -29.48M | -17.11M | -8.54M |
| EBITDA Ratio | -5,419.51% | 0.00% | -795.12% | -733.12% | 0.00% |
| Operating Income | -37.50M | -41.03M | -29.78M | -17.71M | -9.04M |
| Operating Income Ratio | -5,419.51% | 0.00% | -803.05% | -758.83% | 0.00% |
| Total Other Income/Expenses | 74.00K | 3.25M | 56.00K | 225.00K | 448.00K |
| Income Before Tax | -37.43M | -39.48M | -29.72M | -17.49M | -8.59M |
| Income Before Tax Ratio | -5,408.82% | 0.00% | -801.54% | -749.19% | 0.00% |
| Income Tax Expense | 584.00K | -776.00K | 425.00K | 306.00K | 286.00K |
| Net Income | -38.01M | -38.70M | -30.15M | -17.79M | -8.87M |
| Net Income Ratio | -5,493.21% | 0.00% | -813.00% | -762.30% | 0.00% |
| EPS | -2.46 | -3.92 | -3.06 | -2.07 | -1.31 |
| EPS Diluted | -2.46 | -3.92 | -3.06 | -2.07 | -1.31 |
| Weighted Avg Shares Out | 15.45M | 9.86M | 9.86M | 8.58M | 6.77M |
| Weighted Avg Shares Out (Dil) | 15.45M | 9.86M | 9.86M | 8.58M | 6.77M |
Will Ayala Pharmaceuticals, Inc. (AYLA) Report Negative Q2 Earnings? What You Should Know
AYLA Stock Increased 3.3%: Why It Happened
Ayala Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference
Ayala Pharmaceuticals to Participate in Upcoming Virtual Investor Conferences
Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue Estimates
Ayala Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Business Update
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of AL102 in Combination with BCMA Targeting Agent, WVT078, in Patients with relapsed/refractory Multiple Myeloma
Ayala Pharmaceuticals Raises $25M Via Equity To Fund AL102 Development In Connective Tissue Tumors
Ayala Pharmaceuticals Announces $25 Million Strategic Financing
Ayala Pharmaceuticals Announces First Patient Dosed in Phase 2 TENACITY Clinical Trial of AL101 for the Treatment of Patients with Notch-Activated Triple Negative Breast Cancer
Source: https://incomestatements.info
Category: Stock Reports